Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1

Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1

Abstract Introduction Once-daily fixed-dose combinations (FDC) containing abacavir (ABC), dolutegravir (DTG), and lamivudine (3TC) have been approved in the US for adults and children with HIV weighing ≥ 6 kg. This analysis assessed the ability of previously developed ABC, DTG, and 3TC pediatric pop...

Full description

Bibliographic Details
Main Authors: Hardik Chandasana, Sven C. van Dijkman, Rashmi Mehta, Mark Bush, Helena Rabie, Patricia Flynn, Tim R. Cressey, Edward P. Acosta, Kristina M. Brooks, for the IMPAACT 2019 Study Team
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-07-01
Series:Infectious Diseases and Therapy
Subjects:
Dolutegravir
Abacavir
Lamivudine
Population pharmacokinetics
HIV-1
Pediatrics
Online Access:https://doi.org/10.1007/s40121-024-01008-y

Internet

https://doi.org/10.1007/s40121-024-01008-y

Similar Items